Literature DB >> 18835239

The base exchange reaction of NAD+ glycohydrolase: identification of novel heterocyclic alternative substrates.

Frank Preugschat1, Ginger H Tomberlin, David J T Porter.   

Abstract

ADP-ribosyl cyclase and NAD+ glycohydrolase (CD38, E.C.3.2.2.5) efficiently catalyze the exchange of the nicotinamidyl moiety of NAD+, nicotinamide adenine dinucleotide phosphate (NADP+) or nicotinamide mononucleotide (NMN+) with an alternative base. 4'-Pyridinyl drugs (amrinone, milrinone, dismerinone and pinacidil) were efficient alternative substrates (k(cat)/K(M)=0.9-10 microM(-1)s(-1)) in the exchange reaction with ADP-ribosyl cyclase. When CD38 was used as a catalyst the k(cat)/K(M) values for the exchange reaction were reduced two or more orders of magnitude (0.015-0.15 microM(-1)s(-1)). The products of this reaction were novel dinucleotides. The values of the equilibrium constants for dinucleotide formation were determined for several drugs. These enzymes also efficiently catalyze the formation of novel mononucleotides in an exchange reaction with NMN+, k(cat)/K(M)=0.05-0.4 microM(-1)s(-1). The k(cat)/K(M) values for the exchange reaction with NMN+ were generally similar (0.04-0.12 microM(-1)s(-1)) with CD38 and ADP-ribosyl cyclase as catalysts. Several novel heterocyclic alternative substrates were identified as 2-isoquinolines, 1,6-naphthyridines and tricyclic bases. The k(cat)/K(M) values for the exchange reaction with these substrates varied over five orders of magnitude and approached the limit of diffusion with 1,6-naphthyridines. The exchange reaction could be used to synthesize novel mononucleotides or to identify novel reversible inhibitors of CD38.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835239     DOI: 10.1016/j.abb.2008.09.005

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  NAD captureSeq indicates NAD as a bacterial cap for a subset of regulatory RNAs.

Authors:  Hana Cahová; Marie-Luise Winz; Katharina Höfer; Gabriele Nübel; Andres Jäschke
Journal:  Nature       Date:  2014-12-22       Impact factor: 49.962

2.  SPAAC-NAD-seq, a sensitive and accurate method to profile NAD+-capped transcripts.

Authors:  Hao Hu; Nora Flynn; Hailei Zhang; Chenjiang You; Runlai Hang; Xufeng Wang; Huan Zhong; Zhulong Chan; Yiji Xia; Xuemei Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

Review 3.  CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions.

Authors:  Eduardo Nunes Chini
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

4.  A continuous microplate assay for sirtuins and nicotinamide-producing enzymes.

Authors:  Brian C Smith; William C Hallows; John M Denu
Journal:  Anal Biochem       Date:  2009-07-16       Impact factor: 3.365

5.  Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.

Authors:  Yun Shi; Philip S Kerry; Jeffrey D Nanson; Todd Bosanac; Yo Sasaki; Raul Krauss; Forhad K Saikot; Sarah E Adams; Tamim Mosaiab; Veronika Masic; Xianrong Mao; Faith Rose; Eduardo Vasquez; Marieke Furrer; Katie Cunnea; Andrew Brearley; Weixi Gu; Zhenyao Luo; Lou Brillault; Michael J Landsberg; Aaron DiAntonio; Bostjan Kobe; Jeffrey Milbrandt; Robert O Hughes; Thomas Ve
Journal:  Mol Cell       Date:  2022-03-24       Impact factor: 19.328

6.  Complementary NAD+ replacement strategies fail to functionally protect dystrophin-deficient muscle.

Authors:  David W Frederick; Alan V McDougal; Melisa Semenas; Johanna Vappiani; Andrea Nuzzo; John C Ulrich; J David Becherer; Frank Preugschat; Eugene L Stewart; Daniel C Sévin; H Fritz Kramer
Journal:  Skelet Muscle       Date:  2020-10-22       Impact factor: 4.912

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.